Thermo Fisher Scientific Inc. (NYSE:TMO) is Cryder Capital Partners LLP’s 4th Largest Position

Cryder Capital Partners LLP boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 324,801 shares of the medical research company’s stock after acquiring an additional 34,448 shares during the quarter. Thermo Fisher Scientific accounts for 12.3% of Cryder Capital Partners LLP’s portfolio, making the stock its 4th biggest holding. Cryder Capital Partners LLP owned 0.08% of Thermo Fisher Scientific worth $168,971,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Quilter Plc increased its position in Thermo Fisher Scientific by 8.9% in the fourth quarter. Quilter Plc now owns 235,304 shares of the medical research company’s stock worth $122,412,000 after buying an additional 19,148 shares in the last quarter. Harbour Trust & Investment Management Co boosted its stake in shares of Thermo Fisher Scientific by 1.9% in the fourth quarter. Harbour Trust & Investment Management Co now owns 15,672 shares of the medical research company’s stock worth $8,153,000 after acquiring an additional 295 shares during the period. Angeles Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 0.6% in the fourth quarter. Angeles Wealth Management LLC now owns 3,943 shares of the medical research company’s stock worth $2,051,000 after acquiring an additional 22 shares during the period. Newbridge Financial Services Group Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $52,000. Finally, Kestra Private Wealth Services LLC boosted its stake in shares of Thermo Fisher Scientific by 10.4% in the fourth quarter. Kestra Private Wealth Services LLC now owns 11,914 shares of the medical research company’s stock worth $6,198,000 after acquiring an additional 1,118 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock worth $11,231,699 in the last ninety days. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TMO. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. TD Cowen increased their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Bernstein Bank increased their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Finally, Raymond James reaffirmed an “outperform” rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Thermo Fisher Scientific Trading Down 0.2 %

Shares of NYSE TMO opened at $571.44 on Monday. The firm has a market cap of $218.58 billion, a PE ratio of 34.57, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The business has a fifty day simple moving average of $547.34 and a two-hundred day simple moving average of $572.26.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.